Dicloxacillin Sodium hydrate

Cat. No.:	HY-B0977	NaOO
CAS No.:	13412-64-1	
Molecular Formula:	C ₁₉ H ₁₈ Cl ₂ N ₃ NaO ₆ S	
Molecular Weight:	510.32	S ⁻ N H _{Cl} H
Target:	Bacterial; Antibiotic	
Pathway:	Anti-infection	Í I I
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	← CI H ₂ O
	in solvent. by e, o months, zo e, i month (sealed storage, away non-moisture)	120

SOLVENT & SOLUBILITY

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9596 mL	9.7978 mL	19.5955 mL
	5 mM	0.3919 mL	1.9596 mL	3.9191 mL
	10 mM	0.1960 mL	0.9798 mL	1.9596 mL
Please refer to the solubility information to select the appropriate solvent.				

BIOLOGICAL ACTIV	VITY
Description	Dicloxacillin Sodium hydrate (Dicloxacillin sodium salt monohydrate) is a narrow-spectrum β-Lactam antibiotic of the penicillin class, is used to treat infections caused by susceptible Gram-positive bacteria, active against beta-lactamase-producing organisms such as Staphylococcus aureus ^{[1][2][3]} .
IC ₅₀ & Target	β-lactam
In Vitro	Dicloxacillin exhibits EC50 values of 0.06 and 0.50 mg/L in ATCC 25923 and E19977, respectively. Dicloxacillin exhibits MIC values of 0.125 and 0.5 mg/L in ATCC 25923 and E19977 with pH 7.4, respectively ^[3] .MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Viability Assay ^[3] Cell Line:Strains ATCC 25923 and E19977.



	Concentration:	0-500 mg/L.
	Incubation Time: Result:	Up to 24 h.
		Exhibited EC_{50} values of 0.06 and 0.50 mg/L in ATCC 25923 and E19977, respectively.
		erapeutic activity in murine peritonitis-sepsis model and all the mice are survivied ^[4] . ntly confirmed the accuracy of these methods. They are for reference only. Female outbred Swiss Webster mice (Murine peritonitis-sepsis model) ^[4] .
		125 mg/kg.
	Dosage: Administration:	IV injection, single doses.

CUSTOMER VALIDATION

• Biomed Res Int. 2018 Jul 2;2018:3579832.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Jusko WJ, et al. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics. 1975 Dec;56(6):1038-44.

[2]. Miranda-Novales G, et al. In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains. Ann Clin Microbiol Antimicrob. 2006 Oct 12;5:25.

[3]. Anne Sandberg, et al. Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro. Antimicrob Agents Chemother. 2010 Jun;54(6):2391-400.

[4]. John Chu, et al. Discovery of MRSA active antibiotics using primary sequence from the human microbiome. Nat Chem Biol. 2016 Dec;12(12):1004-1006.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA